Galectin‐3 and suppression of tumorigenicity 2: Two emerging cardiac biomarkers that may be predictors of cardiac fibrosis development in sport
Experimental Physiology · 2023
DOI: 10.1113/ep091428 ↗Kurz gefasst
Kommentar in der Zeitschrift Experimental Physiology, 2023. Verfasst von Caroline Le Goff. Beteiligte Einrichtung: Clinical Chemistry Department, University Hospital of Liege, Liege, Belgium. Hauptthemen laut MEDLINE: Fibrosis, Galectin 3, Heart Diseases, Interleukin-1 Receptor-Like 1 Protein. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 7 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Chemistry Department, University Hospital of Liege, Liege, Belgium.
ORCID-Profile: Caroline Le Goff
Zitieren
APA
Goff, C. L. (2023). Galectin‐3 and suppression of tumorigenicity 2: Two emerging cardiac biomarkers that may be predictors of cardiac fibrosis development in sport. Experimental Physiology. https://doi.org/10.1113/ep091428
Vancouver
Goff CL. Galectin‐3 and suppression of tumorigenicity 2: Two emerging cardiac biomarkers that may be predictors of cardiac fibrosis development in sport. Experimental Physiology. 2023. doi:10.1113/ep091428
BibTeX
@article{Goff2023,
author = {Goff, Caroline Le},
title = {Galectin‐3 and suppression of tumorigenicity 2: Two emerging cardiac biomarkers that may be predictors of cardiac fibrosis development in sport},
journal = {Experimental Physiology},
year = {2023},
doi = {10.1113/ep091428}
}
EUVIMED